The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001182381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
3/03/2026
Date registered
Help: Date registered
23/09/2026
Date last updated
Help: Date last updated
23/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
23/09/2026
Date results provided
Help: Date results provided
23/09/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
A study of gentamicin cream to improve wound healing in people with dystrophic epidermolysis bullosa
Scientific title
Double-blind, Randomised, Vehicle-controlled, Phase II, Efficacy and Safety Study of 0.1% Topical Gentamicin in Patients with nonsense variants in COL7A1 resulting in autosomal dominant and recessive forms of Epidermolysis Bullosa
Additional trial identifiers [1] 316682 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Epidermolysis Bullosa 340925 0
Condition category
Condition code
Skin 337078 337078 0 0
Dermatological conditions

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants applied topical gentamicin 0.1% to one randomly allocated target wound in an intra-individual paired-wound design. Each participant contributed two comparable target wounds, with one wound randomised to active treatment and the other to vehicle control.

Treatment was administered for 30 ± 7 days.

Participants applied vehicle (white soft paraffin ointment, identical in appearance and packaging to the active treatment but without gentamicin) to one randomly allocated target wound. In this intra-individual paired-wound design, each participant contributed two comparable target wounds, with one receiving vehicle and the other receiving topical gentamicin 0.1%.

The topical was applied at approximately 1 mm thickness at each dressing change (at least every second day) for a treatment duration of 30 ± 7 days. Wound area measures allowed for individualised mL/g use

Adherence was monitored via return of all unused study medication at the end-of-intervention visit.
Intervention code [1] 333360 0
Treatment: Drugs
Description of the comparator or control
Participants applied vehicle (identical in appearance and formulation base but without active gentamicin) to one randomly allocated target wound. In this intra-individual paired-wound design, each participant contributed two comparable target wounds, with one wound receiving vehicle and the other receiving topical gentamicin 0.1%.

Treatment duration was 30 ± 7 days.

The topical was applied at approximately 1 mm thickness at each dressing change (at least every second day) for a treatment duration of 30 ± 7 days. Wound area measures allowed for individualised mL/g use

Participants applied vehicle (white soft paraffin ointment only, identical in appearance and packaging to the active treatment but without gentamicin)
Control group
Placebo

Outcomes
Primary outcome [1] 344595 0
Proportion of wounds achieving first complete closure within 30 ± 7 days
Timepoint [1] 344595 0
Assessed up to 30 ± 7 days following commencement of treatment.
Primary outcome [2] 344596 0
Time to first complete wound closure
Timepoint [2] 344596 0
Measured from treatment commencement until first documented complete closure, up to 30 ± 7 days following commencement of treatment
Secondary outcome [1] 458552 0
Proportion of wounds achieving complete closure at prespecified timepoints
Timepoint [1] 458552 0
Day 7 ± 5 days following commencement of treatment Day 14 ± 5 days following commencement of treatment Day 30 ± 7 days following commencement of treatment Day 60 ± 7 days following commencement of treatment Day 90 ± 7 days following commencement of treatment
Secondary outcome [2] 458553 0
Percent change in wound size
Timepoint [2] 458553 0
Assessed at scheduled study visits: Day 7 ± 5 days, Day 14 ± 5 days, Day 30 ± 7 days, Day 60 ± 7 days and Day 90 ± 7 days following commencement of treatment
Secondary outcome [3] 458554 0
Time from wound closure to recurrence
Timepoint [3] 458554 0
Measured from first complete closure to documented recurrence, up to Day 90 ± 7 days following commencement of treatment
Secondary outcome [4] 458555 0
Wound infection
Timepoint [4] 458555 0
Assessed at each study visits: Day 7 ± 5 days, Day 14 ± 5 days, Day 30 ± 7 days, Day 60 ± 7 days and Day 90 ± 7 days following commencement of treatment
Secondary outcome [5] 458556 0
Treatment satisfaction (patients greater than or equal to 14 years)
Timepoint [5] 458556 0
Day 7 ± 5 days, Day 14 ± 5 days, Day 30 ± 7 days, Day 60 ± 7 days and Day 90 ± 7 days following commencement of treatment
Secondary outcome [6] 468365 0
Safety/adverse events
Timepoint [6] 468365 0
From first to last dose (D0–D30, followed up 30 days post last dose) following commencement of treatment
Secondary outcome [7] 468366 0
Laboratory testing
Timepoint [7] 468366 0
Timed at D0 and D30 (bloods) and D0/D90 (rectal swab) following commencement of treatment
Secondary outcome [8] 468367 0
Local tolerance
Timepoint [8] 468367 0
Day 7 ± 5 days, Day 14 ± 5 days, Day 30 ± 7 days, Day 60 ± 7 days and Day 90 ± 7 days following commencement of treatment
Secondary outcome [9] 468368 0
Background pain
Timepoint [9] 468368 0
Day 7 ± 5 days, Day 14 ± 5 days, Day 30 ± 7 days, Day 60 ± 7 days and Day 90 ± 7 days following commencement of treatment
Secondary outcome [10] 468369 0
Procedural pain
Timepoint [10] 468369 0
Day 7 ± 5 days, Day 14 ± 5 days, Day 30 ± 7 days, Day 60 ± 7 days and Day 90 ± 7 days following commencement of treatment
Secondary outcome [11] 468370 0
Itch
Timepoint [11] 468370 0
Day 7 ± 5 days, Day 14 ± 5 days, Day 30 ± 7 days, Day 60 ± 7 days and Day 90 ± 7 days following commencement of treatment
Secondary outcome [12] 468371 0
Impact of wounds on sleep
Timepoint [12] 468371 0
Day 7 ± 5 days, Day 14 ± 5 days, Day 30 ± 7 days, Day 60 ± 7 days and Day 90 ± 7 days following commencement of treatment

Eligibility
Key inclusion criteria
Age greater than or equal to 12 months
Confirmed diagnosis of epidermolysis bullosa (EB)
Presence of a nonsense variant in COL7A1
At least two comparable partial-thickness target wounds
Target wounds at least (ie. equal or greater than) 7 cm² in size
Target wounds suitable for intra-individual paired comparison
Ability to provide written informed consent (participant or guardian)
Minimum age
12 Months
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Renal impairment
Auditory impairment
Known allergy or hypersensitivity to aminoglycosides
Recent exposure to gentamicin
Clinically infected target wounds at baseline
Systemic immunosuppression
Prior stem cell therapy for epidermolysis bullosa
Prior gene therapy for epidermolysis bullosa

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The treatment allocation sequence was generated and held by the hospital pharmacy. An unblinded clinical trials pharmacist prepared and dispensed the investigational products according to the randomisation sequence, decanting 0.1% gentamicin or white paraffin into identical amber jars labelled “right” or “left.” Allocation data were stored exclusively by pharmacy. Study investigators enrolled participants but did not have access to the allocation sequence, ensuring concealment of allocation.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A randomisation sequence allocating target wounds in a 1:1 ratio to topical gentamicin or vehicle was generated and held by the hospital pharmacy.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

Intervention assignment
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 29216 0
Sydney Children's Hospital - Randwick
Recruitment postcode(s) [1] 45524 0
2031 - Randwick

Funding & Sponsors
Funding source category [1] 321292 0
Hospital
Name [1] 321292 0
Sydney Children's Hospital
Country [1] 321292 0
Australia
Primary sponsor type
Hospital
Name
Sydney Children's Hospital
Address
Country
Australia
Secondary sponsor category [1] 326033 0
None
Name [1] 326033 0
Address [1] 326033 0
Country [1] 326033 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319822 0
Sydney Children's Hospitals Network Human Research Ethics Committee
Ethics committee address [1] 319822 0
Ethics committee country [1] 319822 0
Australia
Date submitted for ethics approval [1] 319822 0
25/05/2021
Approval date [1] 319822 0
07/06/2021
Ethics approval number [1] 319822 0
2021/ETH00631

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148522 0
Prof Orli Wargon
Address 148522 0
Dept Paediatric Dermatology Sydney Children's Hospital High St Randwick NSW 2031 Australia
Country 148522 0
Australia
Phone 148522 0
+61 2 93821776
Fax 148522 0
Email 148522 0
Contact person for public queries
Name 148523 0
Orli Wargon
Address 148523 0
Dept Paediatric Dermatology Sydney Children's Hospital High St Randwick NSW 2031 Australia
Country 148523 0
Australia
Phone 148523 0
+61 2 93821776
Fax 148523 0
Email 148523 0
Contact person for scientific queries
Name 148524 0
Orli Wargon
Address 148524 0
Dept Paediatric Dermatology Sydney Children's Hospital High St Randwick NSW 2031 Australia
Country 148524 0
Australia
Phone 148524 0
+61 2 93821776
Fax 148524 0
Email 148524 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
A finite period of: 5 years
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

• Postal address: Head of Department
Dept Paediatric Dermatology
Sydney Children's Hospital
High St Randwick NSW 2031
Australia


Are there extra considerations when requesting access to individual participant data?
Yes: costs, institutional policies on data sharing



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
Other filesNo CONSORT Flow diagram CONSORT_2025_flow_diagram.docx

Documents added automatically
No additional documents have been identified.